Basking Biosciences Announces Close of $55 Million Financing to Accelerate Clinical Development for First Reversible Thrombolytic for Ischemic Stroke
Financing will fund upcoming Phase 2 trial of BB-031, a first-in-class RNA aptamer targeting von Willebrand Factor (vWF) in development to treat acute ischemic stroke Financing was led by ARCH Venture Partners Columbus, Ohio – Jan. 30, 2024 – Basking Biosciences (Basking), a clinical-stage biopharmaceutical company developing a novel acute thrombolytic therapy to treat stroke, […]
